Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Gene | FGFR2 |
| Variant | I548Wfs*8 |
| Impact List | frameshift |
| Protein Effect | gain of function - predicted |
| Gene Variant Descriptions | FGFR2 I548Wfs*8 indicates a shift in the reading frame starting at amino acid 548 and terminating 8 residues downstream causing a premature truncation of the 821 amino acid Fgfr2 protein (UniProt.org). I548Wfs*8 results in increased proliferation and invasion in cultured cells (PMID: 37964396), and therefore, is predicted to lead to a gain of Fgfr2 protein function. |
| Associated Drug Resistance | |
| Category Variants Paths |
FGFR2 mutant FGFR2 act mut FGFR2 I548Wfs*8 |
| Transcript | NM_000141.5 |
| gDNA | chr10:g.121498525_121498526insTTCGGGGGGGGGGGGGGGCA |
| cDNA | c.1641_1642insTGCCCCCCCCCCCCCCCGAA |
| Protein | p.I548Wfs*8 |
| Source Database | RefSeq |
| Genome Build | GRCh38/hg38 |
| Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
|---|---|---|---|---|---|
| NM_000141.5 | chr10:g.121498525_121498526insTTCGGGGGGGGGGGGGGGCA | c.1641_1642insTGCCCCCCCCCCCCCCCGAA | p.I548Wfs*8 | RefSeq | GRCh38/hg38 |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR2 I548Wfs*8 | cholangiocarcinoma | sensitive | Infigratinib | Preclinical - Cell culture | Actionable | In a preclinical study, Truseltiq (infigratinib) decreased viability of a cholangiocarcinoma cell line expressing FGFR2 I548Wfs*8 in culture (PMID: 37964396). | 37964396 |